Association of the interleukin-1 receptor antagonist gene polymorphism with asthma, bronchial hyperresponsiveness (BHR) and forced expiratory volume in one second (FEV1)/forced vital capacity (FVC)
| Outcome | rs2234678 | p-value | FDR adjusted | GG versus AA | GA versus AA | ||
| GG | GA | AA | OR (95% CI) | OR (95% CI) | |||
| Asthma at age yrs | |||||||
| 1 | 6/52 (11.5) | 32/325 (9.8) | 57/494 (11.5) | 0.74 | 0.91 | 1.34 (0.51–3.49) | 0.912 (0.54–1.53) |
| 2 | 13/49 (26.5) | 33/297 (11.1) | 59/466 (12.7) | 0.01 | 0.08 | 2.99 (1.38–6.46) | 0.93 (0.57–1.51) |
| 4 | 10/52 (19.2) | 46/311 (14.8) | 77/468 (16.5) | 0.67 | 0.91 | 1.58 (0.74–3.38) | 0.97 (0.63–1.47) |
| 10 | 8/59 (13.6) | 47/343 (13.7) | 79/518 (15.2) | 0.80 | 0.91 | 0.97 (0.41–2.30) | 0.85 (0.56–1.32) |
| Repeated measurement of asthma at ages 1, 2, 4 and 10 yrs# | 242/1721 (14.1) | 142/1150 (12.4) | 35/186 (18.8) | 0.10 | 1.58 (0.93–2.70) | 0.92 (0.67–1.25) | |
| BHR | 22/47 (46.8) | 109/265 (41.1) | 168/388 (43.3) | 0.97 | 0.97 | ||
| Asthma trajectories | |||||||
| Disease-free | 34/59 (57.6) | 239/343 (69.9) | 358/519 (70.0) | Ref. | 1 | 1 | |
| Transient | 14/59(23.7) | 76/343 (22.2) | 114/519 (22.0) | 0.51 | 0.91 | 1.13 (0.82–1.60) | 0.99 (0.85–1.18) |
| Persistent | 6/59 (10.2) | 24/343 (7.0) | 43/519 (8.3) | 0.74 | 0.91 | 1.21 (0.76–1.92) | 0.91 (0.70–1.19) |
| Missing/not defined | 5/59 (8.5) | 4/343 (1.2) | 4/519 (0.8) | ||||
| FEV1/FVC¶ | 0.88 (0.79–0.97) | 0.88 (0.78–0.98) | 0.88 (0.82–0.97) | 0.31 | 0.91 | ||
Data are presented as n/n (%) or mean (5th–95th percentile), unless otherwise stated. Numbers of observations are presented instead of number of children. False discovery rate (FDR) adjusted p-values were calculated using the Benjamini–Hochberg algorithm. OR: odds ratio; 95% CI: 95% confidence interval; Ref.: reference value. #: no FDR adjustment was performed for this variable; ¶: as the FEV1/FVC ratio is a continuous outcome variable, the Kruskal–Wallis Test was used; Chi-squared tests were performed for all other outcomes.